menu
    • menu
    [{"orgOrder":0,"company":"Sirius Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"SRSD107","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase I","graph3":"Sirius Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sirius Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Sirius Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Sirius Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"SRSD107","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase I","graph3":"Sirius Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sirius Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Sirius Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Sirius Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"SRSD107","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase I","graph3":"Sirius Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sirius Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Sirius Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Sirius Therapeutics","sponsor":"BioTrack Capital","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Series B Financing","leadProduct":"SRSD107","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase I","graph3":"Sirius Therapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0.050000000000000003,"dosageForm":"Injection","sponsorNew":"Sirius Therapeutics \/ BioTrack Capital","highestDevelopmentStatusID":"6","companyTruncated":"Sirius Therapeutics \/ BioTrack Capital"},{"orgOrder":0,"company":"Sirius Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"SRSD107","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Sirius Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sirius Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sirius Therapeutics \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Sirius Therapeutics

    Menu

    Sirius Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Sirius Therapeutics

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed

                            Sirius Therapeutics

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SRSD107

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Comparison of SRSD107 & Enoxaparin in Adults Undergoing TKA

                            Details : SRSD107 is a Oligonucleotide drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Venous Thromboembolism.

                            Product Name : Undisclosed

                            Product Type : Oligonucleotide

                            Upfront Cash : Inapplicable

                            August 24, 2025

                            Lead Product(s) : SRSD107

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Sirius Therapeutics

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed

                            Sirius Therapeutics

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SRSD107

                            Therapeutic Area : Hematology

                            Study Phase : Phase I

                            Sponsor : BioTrack Capital

                            Deal Size : $50.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Sirius Raises $50M to Advance siRNA Therapies for Cardiometabolic Diseases

                            Details : The funds from this round will further advance clinical programs and expand pipeline including SRSD107, which is being evaluated for the treatment of thromboembolic disorders.

                            Product Name : Undisclosed

                            Product Type : Oligonucleotide

                            Upfront Cash : Undisclosed

                            May 09, 2025

                            Lead Product(s) : SRSD107

                            Therapeutic Area : Hematology

                            Highest Development Status : Phase I

                            Sponsor : BioTrack Capital

                            Deal Size : $50.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Sirius Therapeutics

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed

                            Sirius Therapeutics

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SRSD107

                            Therapeutic Area : Hematology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Sirius Shares Promising Phase 1 Data for Factor XI siRNA in Thromboembolic Disorders

                            Details : SRSD107 is a Factor XI inhibitor siRNA drug candidate, which is currently being evaluated for the treatment of thromboembolic disorders.

                            Product Name : Undisclosed

                            Product Type : Oligonucleotide

                            Upfront Cash : Inapplicable

                            December 10, 2024

                            Lead Product(s) : SRSD107

                            Therapeutic Area : Hematology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Sirius Therapeutics

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed

                            Sirius Therapeutics

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SRSD107

                            Therapeutic Area : Hematology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Sirius Therapeutics Announces Submission to Begin First Clinical Trial of Factor XI siRNA

                            Details : SRSD107 is a novel double-stranded small interfering ribonucleic acid (siRNA). it specifically targets coagulation factor XI (FXI) mRNA and inhibits FXI protein expression, thereby blocking the intrinsic coagulation pathway and promoting anticoagulant/an...

                            Product Name : Undisclosed

                            Product Type : Oligonucleotide

                            Upfront Cash : Inapplicable

                            November 09, 2023

                            Lead Product(s) : SRSD107

                            Therapeutic Area : Hematology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Sirius Therapeutics

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed

                            Sirius Therapeutics

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SRSD107

                            Therapeutic Area : Hematology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Phase 1 Study to Evaluate the Safety, Tolerability, PK/PD of SRSD107 in Healthy Participants

                            Details : SRSD107 is a Oligonucleotide drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Thrombosis.

                            Product Name : Undisclosed

                            Product Type : Oligonucleotide

                            Upfront Cash : Inapplicable

                            November 03, 2023

                            Lead Product(s) : SRSD107

                            Therapeutic Area : Hematology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth